Management of Bullae

Diagnosis and Assessment

The management of bullae depends critically on distinguishing between autoimmune blistering disease and infectious causes, as these require fundamentally different and time-sensitive treatments, according to the American College of Dermatology 1, 2
For autoimmune bullous pemphigoid, look for tense blisters on erythematous or normal-appearing skin of limbs and trunk in elderly patients, as recommended by the British Association of Dermatologists 3, 4
Pruritus may precede bullae by weeks to months in patients with bullous pemphigoid, as noted by the British Association of Dermatologists 3
Associated with neurological disease, such as cerebrovascular disease, dementia, Parkinson's, and epilepsy, in patients with bullous pemphigoid, according to the British Association of Dermatologists 3
Critical warning signs for infectious causes with bullae include pain disproportionate to physical findings, violaceous bullae, cutaneous hemorrhage, skin sloughing, skin anesthesia, rapid progression, and gas in tissue, as indicated by the Infectious Diseases Society of America 2
Systemic toxicity, including fever, tachycardia, and hypotension, is a critical warning sign for infectious causes with bullae, according to the Infectious Diseases Society of America 2

Superpotent topical corticosteroids, such as clobetasol propionate, are the first-line treatment for bullous pemphigoid, providing better disease control with significantly lower mortality compared to systemic corticosteroids, as recommended by the American Academy of Dermatology 1
For localized disease, apply superpotent topical corticosteroids directly to lesions only, and escalate to systemic therapy if no improvement within 3-7 days, according to the American Academy of Dermatology 1, 5
For generalized disease, apply clobetasol propionate 20g per day over entire body except face, and increase to 40g per day if disease control not achieved within 1-3 weeks, as recommended by the American Academy of Dermatology 1
Assess response after 1-3 weeks, and begin tapering after 15 days once disease control achieved, according to the American Academy of Dermatology 1
Continue maintenance therapy for 8 months, with a total treatment duration of 12 months, as recommended by the American Academy of Dermatology 1

Hospitalize immediately for parenteral antibiotics and emergent surgical consultation if necrotizing fasciitis is suspected, as recommended by the Infectious Diseases Society of America 2
Obtain Gram stain and culture of pus/exudates, and blood cultures if systemic symptoms are present, according to the Infectious Diseases Society of America 2
Empiric antibiotic therapy should be started immediately, with options including clindamycin plus penicillin for group A streptococcal/clostridial infections, and vancomycin plus piperacillin/tazobactam for polymicrobial infections, as recommended by the Infectious Diseases Society of America 2
Decompress intact bullae by piercing with sterile needle, and gently cleanse with antimicrobial solution before and after drainage, according to the Infectious Diseases Society of America 2

Monitor patients with bullous pemphigoid every 2 weeks for the first 3 months, and monthly for the next 3 months, as recommended by the American Academy of Dermatology 1, 5
Reevaluate patients with infectious bullae within 24-48 hours to ensure appropriate response, and consider burn unit admission for extensive skin involvement, according to the Infectious Diseases Society of America 2

Never use oral prednisone >0.75 mg/kg/day in bullous pemphigoid, as it is associated with significant mortality in elderly patients, as warned by the American Academy of Dermatology 1, 5
Implement osteoporosis prevention when using systemic corticosteroids, as recommended by the American Academy of Dermatology 1
Discontinue minocycline if hyperpigmentation, pneumonia, or eosinophilia develop, according to the American Academy of Dermatology 1
Positive DIF or BP180 ELISA >27 U/mL indicates increased relapse risk, as noted by the American Academy of Dermatology 1

The nursing home setting and end-stage Parkinson's disease increase the risk for autoimmune blistering disease, such as bullous pemphigoid, in elderly patients 6

Negative fungal stain definitively rules out active fungal infection, indicating that saprophytic fungi are environmental contaminants or colonizers that do not cause disease 7, 8
Bullous lesions create a moist, damaged environment that allows secondary colonization by non-pathogenic organisms, such as saprophytic fungi 8

If bullous pemphigoid is confirmed, treatment should focus on immunosuppression, not antimicrobials, with superpotent topical corticosteroids as first-line treatment for extensive disease 6
Alternative options for elderly or frail patients include anti-inflammatory antibiotics, such as doxycycline, with or without nicotinamide, which may be safer and avoid steroid-related complications 6

Do not treat the saprophytic fungus with antifungals, as this will not improve the bullous lesions and may delay appropriate diagnosis and treatment of the underlying autoimmune condition 7, 8
Do not assume infection based on culture alone, as the negative fungal stain is definitive evidence that no invasive fungal infection is present 7, 8
Do not use high-dose systemic steroids as first-line treatment, as topical therapy or anti-inflammatory antibiotics are safer initial options for elderly, frail patients with Parkinson's disease 6